1. Home
  2. EXTR vs ACAD Comparison

EXTR vs ACAD Comparison

Compare EXTR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extreme Networks Inc.

EXTR

Extreme Networks Inc.

HOLD

Current Price

$22.84

Market Cap

3.9B

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$29.63

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXTR
ACAD
Founded
1996
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.3B
IPO Year
1999
2000

Fundamental Metrics

Financial Performance
Metric
EXTR
ACAD
Price
$22.84
$29.63
Analyst Decision
Strong Buy
Buy
Analyst Count
5
22
Target Price
$21.20
$30.55
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
616.67
69.12
EPS
0.31
0.20
Revenue
$1,283,593,000.00
$726,437,000.00
Revenue This Year
$13.33
$18.80
Revenue Next Year
$7.97
$11.70
P/E Ratio
$73.00
$152.85
Revenue Growth
12.59
40.45
52 Week Low
$13.48
$19.69
52 Week High
$33.73
$30.96

Technical Indicators

Market Signals
Indicator
EXTR
ACAD
Relative Strength Index (RSI) 34.26 61.26
Support Level $22.33 $25.00
Resistance Level $25.20 $30.96
Average True Range (ATR) 0.82 0.88
MACD -0.09 -0.02
Stochastic Oscillator 20.62 62.42

Price Performance

Historical Comparison
EXTR
ACAD

About EXTR Extreme Networks Inc.

Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: